Early cancer detection remains one of the biggest challenges in oncology, with many cancers going undetected until later stages when treatment options are more limited. Advances in multi-cancer early detection (MCED) aim to address this by identifying multiple cancer types through a single test, often using a simple blood draw.
Speakers:
- Dr. Tina Clarke Dur, Vice President of Epidemiology and Distinguished Scientist at GRAIL
- Dr. Gary Pestano, Chief Development Officer at Biodesix
- Kevin Billings, Director of Business Segment – Stabilization at Streck
Featured Products
For Research Use Only
Nucleic Acid Plus BCT™
Stabilizes cfDNA, cfRNA, EVs and plasma proteins in whole blood for up to 7 days at room temperature.
For In Vitro Diagnostic Use
Cell-Free DNA BCT®
Stabilizes cell-free DNA and CTCs for up to 7 days, supporting liquid biopsy assays cleared for use with the tube.
Partner With Us
Streck Tube Early Innovators Program
The Early Innovators Program is designed for assay developers and translational researchers ready to evaluate stabilization firsthand with discounted access to tubes, expert guidance and dedicated support to help you validate with confidence.
